Share Twitter LinkedIn Facebook Email Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Ongoing Trials For CLL Patients At The 60th ASH Annual Meeting on Dec 1, 2018.
Positive Outcomes & Tolerability Sonrotoclax + Zanubrutinib in TN-CLL/SLL – ASH 2023 Updates Chronic Lymphocytic Leukemia 1 Min Read
BTK Inhibitor Use and Social Determinants in CLL / SLL [ASH 2023] Chronic Lymphocytic Leukemia 2 Mins Read
Elevate-TN: Treatment-Naive CLL Treated with Acalabrutinib – ASH Chronic Lymphocytic Leukemia 2 Mins Read